

Table 4.25

## Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	299,215	99.4%	238,533	99.5%	32,760	99.3%	23,931	99.3%	1,240	99.0%	31,465	99.2%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	147	0.0%	117	0.0%	21	0.1%	-	-	-	-	-	-
Adenocarcinoma <sup>e</sup>	293,284	97.4%	234,031	97.6%	31,784	96.3%	23,586	97.8%	1,216	97.0%	30,807	97.1%
Adenocarcinoma, NOS (8140)	2,142	0.7%	1,670	0.7%	292	0.9%	139	0.6%	-	-	235	0.7%
Infiltrating duct carcinoma (8500)	220,968	73.4%	174,157	72.6%	24,903	75.5%	18,909	78.4%	974	77.7%	23,640	74.5%
Lobular carcinoma, NOS (8520)	27,753	9.2%	23,645	9.9%	2,397	7.3%	1,366	5.7%	95	7.6%	2,418	7.6%
Inflammatory adenocarcinoma (8530)	939	0.3%	749	0.3%	129	0.4%	51	0.2%	-	-	140	0.4%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,566	9.2%	22,940	9.6%	2,458	7.4%	1,862	7.7%	80	6.4%	3,000	9.5%
Mucinous adenocarcinoma (8480,8482)	5,724	1.9%	4,439	1.9%	645	2.0%	572	2.4%	22	1.8%	552	1.7%
Mucin-producing adenocarcinoma (8481)	67	0.0%	47	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	1,719	0.6%	1,523	0.6%	99	0.3%	89	0.4%	-	-	134	0.4%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,848	0.6%	1,303	0.5%	303	0.9%	210	0.9%	-	-	193	0.6%
Paget disease (8540-8543)	1,156	0.4%	910	0.4%	122	0.4%	109	0.5%	-	-	131	0.4%
Other adenocarcinomas <sup>f</sup>	3,402	1.1%	2,648	1.1%	422	1.3%	275	1.1%	-	-	357	1.1%
Other specific carcinomas <sup>g</sup>	2,466	0.8%	1,839	0.8%	448	1.4%	151	0.6%	-	-	311	1.0%
Medullary adenocarcinoma (8510-8513)	773	0.3%	525	0.2%	194	0.6%	48	0.2%	-	-	150	0.5%
Other <sup>h</sup>	1,693	0.6%	1,314	0.5%	254	0.8%	103	0.4%	-	-	161	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,318	1.1%	2,546	1.1%	507	1.5%	187	0.8%	-	-	336	1.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>f</sup> Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>g</sup> Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

<sup>h</sup> Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

## Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	335	0.1%	255	0.1%	50	0.2%	24	0.1%	-	-	32	0.1%
Hemangiosarcomas (9120-9126,9170)	161	0.1%	138	0.1%	-	-	-	-	-	-	-	-
Other sarcomas <sup>d</sup>	174	0.1%	117	0.0%	37	0.1%	-	-	-	-	21	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	754	0.3%	539	0.2%	93	0.3%	111	0.5%	-	-	134	0.4%
Phyllodes tumor, malignant (9020)	638	0.2%	451	0.2%	72	0.2%	104	0.4%	-	-	113	0.4%
Other <sup>e</sup>	116	0.0%	88	0.0%	21	0.1%	-	-	-	-	21	0.1%
Unspecified (8000-8005)	666	0.2%	498	0.2%	93	0.3%	45	0.2%	-	-	85	0.3%
Total <sup>f</sup>	300,970	100.0%	239,825	100.0%	32,996	100.0%	24,111	100.0%	1,253	100.0%	31,716	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

<sup>e</sup> Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

<sup>f</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	76,141	99.9%	58,824	99.9%	8,413	99.8%	7,627	99.9%	267	100.0%	7,484	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>e</sup>	64,696	84.8%	49,379	83.8%	7,385	87.6%	6,930	90.8%	234	87.6%	6,433	85.8%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,557	8.6%	4,913	8.3%	774	9.2%	762	10.0%	21	7.9%	653	8.7%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,243	6.9%	4,125	7.0%	498	5.9%	540	7.1%	22	8.2%	449	6.0%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	22,102	29.0%	17,159	29.1%	2,481	29.4%	2,071	27.1%	86	32.2%	2,161	28.8%
Comedocarcinoma <i>in situ</i> (8501/2)	6,258	8.2%	4,762	8.1%	680	8.1%	723	9.5%	34	12.7%	588	7.8%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,171	1.5%	801	1.4%	205	2.4%	142	1.9%	-	-	125	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	268	0.4%	164	0.3%	43	0.5%	61	0.8%	-	-	31	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,272	1.7%	995	1.7%	163	1.9%	94	1.2%	-	-	137	1.8%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	21,637	28.4%	16,326	27.7%	2,531	30.0%	2,495	32.7%	64	24.0%	2,274	30.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,761	11.5%	7,323	12.4%	733	8.7%	462	6.1%	29	10.9%	817	10.9%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,743	11.5%	7,309	12.4%	730	8.7%	462	6.1%	28	10.5%	816	10.9%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	18	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,166	2.8%	1,739	3.0%	231	2.7%	169	2.2%	-	-	185	2.5%
Other adenocarcinomas <sup>g</sup>	512	0.7%	380	0.6%	63	0.7%	64	0.8%	-	-	49	0.7%
Other <i>in situ</i> histologies <sup>h</sup>	111	0.1%	84	0.1%	-	-	-	-	-	-	-	-
Total	76,252	100.0%	58,908	100.0%	8,428	100.0%	7,632	100.0%	267	100.0%	7,495	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>g</sup> CIS = Carcinoma *in situ*.

<sup>h</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>i</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

## Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,162	98.1%	12,048	98.3%	2,262	97.2%	1,480	98.1%	128	99.2%	3,566	98.2%
Epidermoid carcinoma <sup>d</sup> (8050-8131)	10,803	65.6%	7,832	63.9%	1,754	75.4%	972	64.5%	78	60.5%	2,437	67.1%
Squamous cell carcinoma (8070)	7,524	45.7%	5,431	44.3%	1,254	53.9%	662	43.9%	58	45.0%	1,558	42.9%
Squamous cell, keratinizing (8071)	1,140	6.9%	801	6.5%	201	8.6%	113	7.5%	-	-	306	8.4%
Squamous cell, non-keratinizing (8072)	1,460	8.9%	1,090	8.9%	199	8.6%	143	9.5%	-	-	409	11.3%
Squamous cell, Microinvasive (8076)	424	2.6%	322	2.6%	58	2.5%	31	2.1%	-	-	103	2.8%
Other (8050-8069, 8073-8075,8077-8131)	255	1.5%	188	1.5%	42	1.8%	23	1.5%	-	-	61	1.7%
Adenocarcinoma <sup>e</sup>	4,655	28.2%	3,716	30.3%	391	16.8%	439	29.1%	43	33.3%	981	27.0%
Adenocarcinoma, NOS (8140)	2,488	15.1%	2,001	16.3%	207	8.9%	222	14.7%	20	15.5%	544	15.0%
Adenosquamous (8560,8570)	553	3.4%	413	3.4%	63	2.7%	70	4.6%	-	-	117	3.2%
Other adenocarcinomas <sup>f</sup>	1,614	9.8%	1,302	10.6%	121	5.2%	147	9.7%	18	14.0%	320	8.8%
Other specific carcinomas <sup>g</sup>	265	1.6%	192	1.6%	41	1.8%	29	1.9%	-	-	43	1.2%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	439	2.7%	308	2.5%	76	3.3%	40	2.7%	-	-	105	2.9%
Sarcoma <sup>h</sup>	59	0.4%	38	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	163	1.0%	105	0.9%	33	1.4%	19	1.3%	-	-	32	0.9%
Unspecified (8000-8005)	96	0.6%	69	0.6%	17	0.7%	-	-	-	-	21	0.6%
Total	16,480	100.0%	12,260	100.0%	2,327	100.0%	1,508	100.0%	129	100.0%	3,633	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

<sup>g</sup> Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>h</sup> Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

## Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	178,971	99.4%	139,391	99.4%	21,893	99.4%	14,568	99.4%	1,018	99.6%	18,902	99.4%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	1,122	0.6%	958	0.7%	116	0.5%	25	0.2%	-	-	97	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	1,069	0.6%	918	0.7%	110	0.5%	24	0.2%	-	-	94	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	167,109	92.8%	131,344	93.7%	19,763	89.8%	13,494	92.1%	946	92.6%	17,541	92.2%
Adenocarcinoma, NOS (8140)	114,952	63.8%	90,084	64.3%	13,712	62.3%	9,625	65.7%	675	66.0%	12,150	63.9%
Adenocarcinoma in adenomatous polyp (8210)	15,085	8.4%	11,699	8.3%	1,701	7.7%	1,309	8.9%	105	10.3%	1,343	7.1%
Adenocarcinoma in villous adenoma (8261)	3,977	2.2%	3,184	2.3%	440	2.0%	299	2.0%	16	1.6%	535	2.8%
Mucinous adenocarcinoma (8470-8473,8480,8482)	11,517	6.4%	9,477	6.8%	1,192	5.4%	737	5.0%	50	4.9%	1,335	7.0%
Mucin-producing adenocarcinoma (8481)	1,571	0.9%	1,251	0.9%	211	1.0%	100	0.7%	-	-	155	0.8%
Signet ring adenocarcinoma (8490)	2,082	1.2%	1,707	1.2%	198	0.9%	152	1.0%	-	-	227	1.2%
Other adenocarcinomas <sup>e</sup>	17,925	10.0%	13,942	9.9%	2,309	10.5%	1,272	8.7%	90	8.8%	1,796	9.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	9,207	5.1%	5,901	4.2%	1,813	8.2%	946	6.5%	53	5.2%	1,090	5.7%
Neuroendocrine carcinoid (8240-8245)	6,785	3.8%	4,111	2.9%	1,443	6.6%	762	5.2%	44	4.3%	858	4.5%
Other <sup>f</sup>	2,422	1.3%	1,790	1.3%	370	1.7%	184	1.3%	-	-	232	1.2%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,533	0.9%	1,188	0.8%	201	0.9%	103	0.7%	16	1.6%	174	0.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>f</sup> Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

## Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	108	0.1%	88	0.1%	-	-	-	-	-	-	21	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	293	0.2%	200	0.1%	49	0.2%	43	0.3%	-	-	33	0.2%
Unspecified (8000-8005)	670	0.4%	496	0.4%	65	0.3%	41	0.3%	-	-	69	0.4%
Total <sup>d</sup>	180,042	100.0%	140,175	100.0%	22,019	100.0%	14,658	100.0%	1,022	100.0%	19,025	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

## Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	18,774	99.1%	15,832	99.1%	1,946	99.2%	806	99.3%	80	100.0%	1,414	98.8%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	6,239	32.9%	4,072	25.5%	1,553	79.2%	557	68.6%	26	32.5%	524	36.6%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,220	32.8%	4,062	25.4%	1,545	78.7%	556	68.5%	26	32.5%	523	36.5%
Adenocarcinoma <sup>e</sup>	11,697	61.7%	11,036	69.1%	325	16.6%	217	26.7%	49	61.3%	822	57.4%
Other specific carcinomas <sup>f</sup>	292	1.5%	246	1.5%	26	1.3%	-	-	-	-	22	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	546	2.9%	478	3.0%	42	2.1%	17	2.1%	-	-	46	3.2%
Other specific types <sup>g</sup>	57	0.3%	48	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	114	0.6%	97	0.6%	-	-	-	-	-	-	-	-
Total	18,945	100.0%	15,977	100.0%	1,962	100.0%	812	100.0%	80	100.0%	1,431	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>g</sup> Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

<sup>h</sup> Other specific types includes sarcomas and other soft tissue tumors.

<sup>i</sup> Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

## Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	22,895	97.1%	16,232	97.0%	2,932	97.6%	3,360	97.5%	199	96.6%	3,900	95.7%
Hepatocellular carcinoma <sup>d</sup> (8170-8175)	17,407	73.8%	11,941	71.3%	2,452	81.6%	2,703	78.4%	163	79.1%	3,070	75.3%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	4,523	19.2%	3,586	21.4%	350	11.7%	535	15.5%	31	15.0%	681	16.7%
Other carcinoma <sup>e</sup>	965	4.1%	705	4.2%	130	4.3%	122	3.5%	-	-	149	3.7%
Other specific carcinoma <sup>f</sup>	603	2.6%	441	2.6%	74	2.5%	84	2.4%	-	-	94	2.3%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	362	1.5%	264	1.6%	56	1.9%	38	1.1%	-	-	55	1.3%
Hepatoblastoma (8970)	233	1.0%	167	1.0%	26	0.9%	30	0.9%	-	-	74	1.8%
Sarcoma <sup>g</sup>	208	0.9%	159	0.9%	19	0.6%	27	0.8%	-	-	37	0.9%
Hemangiosarcoma (9120)	90	0.4%	69	0.4%	-	-	-	-	-	-	-	-
Other sarcomas <sup>h</sup>	118	0.5%	90	0.5%	-	-	-	-	-	-	24	0.6%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	46	0.2%	35	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	190	0.8%	144	0.9%	20	0.7%	24	0.7%	-	-	51	1.3%
Total <sup>d</sup>	23,576	100.0%	16,739	100.0%	3,004	100.0%	3,446	100.0%	206	100.0%	4,077	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

<sup>f</sup> Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

<sup>g</sup> Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

<sup>h</sup> Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

<sup>i</sup> Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.



Table 15.28

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	50.6	226,919	99.7%	185,872	99.7%	25,658	99.7%	13,765	99.7%	778	99.1%	13,158	99.5%
Small cell (8002,8041-8045)	6.6	29,925	13.2%	25,960	13.9%	2,692	10.5%	1,048	7.6%	135	17.2%	1,432	10.8%
Non-small cell	42.5	190,182	83.6%	154,490	82.9%	22,082	85.8%	12,272	88.9%	616	78.5%	11,203	84.7%
Squamous and transitional cell <sup>d</sup>	11.8	52,264	23.0%	43,585	23.4%	6,159	23.9%	2,131	15.4%	221	28.2%	2,557	19.3%
Adenocarcinoma <sup>e</sup>	22.8	102,363	45.0%	81,747	43.9%	11,597	45.1%	8,353	60.5%	265	33.8%	6,356	48.0%
Large cell <sup>f</sup>	0.9	4,152	1.8%	3,400	1.8%	558	2.2%	170	1.2%	-	-	213	1.6%
Non-small cell carcinoma <sup>g</sup>	4.4	19,822	8.7%	15,859	8.5%	2,679	10.4%	1,107	8.0%	92	11.7%	1,195	9.0%
Other specified carcinomas <sup>h</sup>	2.6	11,581	5.1%	9,899	5.3%	1,089	4.2%	511	3.7%	27	3.4%	882	6.7%
Carcinoma, NOS <sup>i</sup>	1.5	6,812	3.0%	5,422	2.9%	884	3.4%	445	3.2%	27	3.4%	523	4.0%
Sarcoma <sup>j</sup>	0.1	447	0.2%	369	0.2%	44	0.2%	26	0.2%	-	-	53	0.4%
Other specified types <sup>k</sup>	0.0	197	0.1%	162	0.1%	24	0.1%	-	-	-	-	18	0.1%
Total	50.7	227,563	100.0%	186,403	100.0%	25,726	100.0%	13,802	100.0%	785	100.0%	13,229	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>f</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>g</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>h</sup> Non-small cell carcinoma includes histology 8046.

<sup>i</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>j</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>k</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Males by Race

Histology <sup>a</sup>	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	59.8	119,450	99.7%	96,638	99.7%	14,244	99.7%	7,693	99.7%	417	99.5%	6,884	99.4%
Small cell (8002,8041-8045)	7.3	14,892	12.4%	12,743	13.1%	1,352	9.5%	692	9.0%	64	15.3%	762	11.0%
Non-small cell	50.5	100,721	84.1%	80,913	83.5%	12,344	86.4%	6,728	87.2%	339	80.9%	5,813	83.9%
Squamous and transitional cell <sup>d</sup>	16.6	32,725	27.3%	27,037	27.9%	3,904	27.3%	1,537	19.9%	131	31.3%	1,609	23.2%
Adenocarcinoma <sup>e</sup>	24.5	49,117	41.0%	38,679	39.9%	6,001	42.0%	4,100	53.2%	135	32.2%	2,995	43.2%
Large cell <sup>f</sup>	1.1	2,343	2.0%	1,893	2.0%	331	2.3%	106	1.4%	-	-	126	1.8%
Non-small cell carcinoma <sup>g</sup>	5.6	11,233	9.4%	8,847	9.1%	1,574	11.0%	709	9.2%	57	13.6%	693	10.0%
Other specified carcinomas <sup>h</sup>	2.6	5,303	4.4%	4,457	4.6%	534	3.7%	276	3.6%	-	-	390	5.6%
Carcinoma, NOS <sup>i</sup>	2.0	3,837	3.2%	2,982	3.1%	548	3.8%	273	3.5%	-	-	309	4.5%
Sarcoma <sup>j</sup>	0.1	254	0.2%	212	0.2%	26	0.2%	-	-	-	-	30	0.4%
Other specified types <sup>k</sup>	0.1	124	0.1%	104	0.1%	-	-	-	-	-	-	-	-
Total	59.9	119,828	100.0%	96,954	100.0%	14,284	100.0%	7,713	100.0%	419	100.0%	6,926	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>e</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>f</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>g</sup> Non-small cell carcinoma includes histology 8046.

<sup>h</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>i</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>j</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

## Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	43.7	107,469	99.8%	89,234	99.8%	11,414	99.8%	6,072	99.7%	361	98.6%	6,274	99.5%
Small cell (8002,8041-8045)	6.1	15,033	14.0%	13,217	14.8%	1,340	11.7%	356	5.8%	71	19.4%	670	10.6%
Non-small cell	36.5	89,461	83.0%	73,577	82.3%	9,738	85.1%	5,544	91.0%	277	75.7%	5,390	85.5%
Squamous and transitional cell <sup>d</sup>	8.1	19,539	18.1%	16,548	18.5%	2,255	19.7%	594	9.8%	90	24.6%	948	15.0%
Adenocarcinoma <sup>e</sup>	21.6	53,246	49.4%	43,068	48.1%	5,596	48.9%	4,253	69.8%	130	35.5%	3,361	53.3%
Large cell <sup>f</sup>	0.7	1,809	1.7%	1,507	1.7%	227	2.0%	64	1.1%	-	-	87	1.4%
Non-small cell carcinoma <sup>g</sup>	3.5	8,589	8.0%	7,012	7.8%	1,105	9.7%	398	6.5%	35	9.6%	502	8.0%
Other specified carcinomas <sup>h</sup>	2.6	6,278	5.8%	5,442	6.1%	555	4.9%	235	3.9%	-	-	492	7.8%
Carcinoma, NOS <sup>i</sup>	1.2	2,975	2.8%	2,440	2.7%	336	2.9%	172	2.8%	-	-	214	3.4%
Sarcoma <sup>j</sup>	0.1	193	0.2%	157	0.2%	18	0.2%	-	-	-	-	23	0.4%
Other specified types <sup>k</sup>	0.0	73	0.1%	58	0.1%	-	-	-	-	-	-	-	-
Total	43.8	107,735	100.0%	89,449	100.0%	11,442	100.0%	6,089	100.0%	366	100.0%	6,303	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

<sup>e</sup> Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

<sup>f</sup> Large cell includes histologies 8012-8014, 8021, 8034, 8082.

<sup>g</sup> Non-small cell carcinoma includes histology 8046.

<sup>h</sup> Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

<sup>i</sup> Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

<sup>j</sup> Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

<sup>k</sup> Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

## Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
All Races, Both Sexes, by site

Histology <sup>a</sup>	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma <sup>b</sup> (8051-8131)	43,177	84.8%	2,839	94.1%	14,862	97.4%	1,244	22.0%	2,440	95.7%
Squamous cell carcinoma (8070-8078,8083-8084)	42,191	82.8%	2,736	90.7%	14,614	95.8%	1,194	21.2%	2,417	94.8%
Adenocarcinoma <sup>c</sup>	5,046	9.9%	122	4.0%	213	1.4%	3,472	61.5%	78	3.1%
Other specific carcinomas <sup>d</sup>	466	0.9%	-	-	31	0.2%	269	4.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,612	3.2%	-	-	81	0.5%	439	7.8%	-	-
Sarcoma and soft tissue <sup>e</sup>	163	0.3%	-	-	21	0.1%	34	0.6%	-	-
Other specific types <sup>f</sup>	270	0.5%	24	0.8%	-	-	115	2.0%	-	-
Unspecified (8000-8005)	200	0.4%	-	-	39	0.3%	71	1.3%	-	-
Total	50,935	100.0%	3,017	100.0%	15,262	100.0%	5,644	100.0%	2,549	100.0%

  

Histology <sup>a</sup>	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma <sup>b</sup> (8051-8131)	5,497	81.8%	1,766	63.3%	10,954	97.8%	2,737	97.3%	838	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,247	78.0%	1,621	58.1%	10,818	96.6%	2,718	96.7%	826	87.8%
Adenocarcinoma <sup>c</sup>	988	14.7%	87	3.1%	57	0.5%	-	-	17	1.8%
Other specific carcinomas <sup>d</sup>	36	0.5%	42	1.5%	41	0.4%	17	0.6%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	60	0.9%	832	29.8%	103	0.9%	31	1.1%	42	4.5%
Sarcoma and soft tissue <sup>e</sup>	31	0.5%	35	1.3%	-	-	-	-	-	-
Other specific types <sup>f</sup>	91	1.4%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	20	0.3%	17	0.6%	20	0.2%	-	-	21	2.2%
Total	6,724	100.0%	2,791	100.0%	11,195	100.0%	2,812	100.0%	941	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>c</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>d</sup> Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

<sup>e</sup> Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

<sup>f</sup> Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,657	91.6%	20,368	92.2%	2,027	88.0%	1,986	90.8%	133	89.9%	3,037	87.2%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	195	0.7%	154	0.7%	18	0.8%	21	1.0%	-	-	34	1.0%
Adenocarcinoma <sup>e</sup>	22,673	84.2%	18,826	85.2%	1,761	76.5%	1,838	84.0%	120	81.1%	2,749	78.9%
Adenocarcinoma, NOS (8140)	3,016	11.2%	2,435	11.0%	380	16.5%	169	7.7%	16	10.8%	322	9.2%
Papillary adenocarcinoma, NOS (8050,8260)	300	1.1%	249	1.1%	34	1.5%	-	-	-	-	40	1.1%
Clear cell adenocarcinoma (8310,9110)	1,449	5.4%	1,097	5.0%	67	2.9%	271	12.4%	-	-	159	4.6%
Endometrioid carcinoma (8380-8383,8570)	2,665	9.9%	2,202	10.0%	133	5.8%	302	13.8%	-	-	406	11.7%
Cystadenocarcinoma, NOS (8440,8450)	76	0.3%	59	0.3%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	7,000	26.0%	5,936	26.9%	509	22.1%	467	21.4%	48	32.4%	746	21.4%
Papillary serous cystadenocarcinoma (8460-8462)	5,360	19.9%	4,563	20.6%	434	18.8%	320	14.6%	24	16.2%	662	19.0%
Mucinous cystadenocarcinoma (8470-8473)	356	1.3%	283	1.3%	23	1.0%	46	2.1%	-	-	50	1.4%
Mucinous adenocarcinoma (8480,8482)	999	3.7%	783	3.5%	85	3.7%	112	5.1%	-	-	144	4.1%
Mucin-producing adenocarcinoma(8481)	31	0.1%	23	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma <sup>f</sup>	1,421	5.3%	1,196	5.4%	82	3.6%	130	5.9%	-	-	204	5.9%
Other specific carcinomas <sup>g</sup>	640	2.4%	454	2.1%	132	5.7%	42	1.9%	-	-	103	3.0%
Stromal cell tumor (8620-8631,8650)	453	1.7%	309	1.4%	107	4.6%	26	1.2%	-	-	76	2.2%
Other <sup>h</sup>	187	0.7%	145	0.7%	25	1.1%	16	0.7%	-	-	27	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,149	4.3%	934	4.2%	116	5.0%	85	3.9%	-	-	151	4.3%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).  
Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

<sup>g</sup> Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

<sup>h</sup> Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>i</sup> Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	86	0.3%	58	0.3%	18	0.8%	-	-	-	-	19	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,867	6.9%	1,439	6.5%	213	9.2%	175	8.0%	-	-	385	11.1%
Mullerian mixed tumor (8950-8951,8980)	828	3.1%	701	3.2%	66	2.9%	48	2.2%	-	-	87	2.5%
Teratoma, malignant (9080-9085,9102)	414	1.5%	274	1.2%	65	2.8%	59	2.7%	-	-	150	4.3%
Other	625	2.3%	464	2.1%	82	3.6%	68	3.1%	-	-	148	4.3%
Unspecified (8000-8005)	303	1.1%	232	1.0%	45	2.0%	18	0.8%	-	-	41	1.2%
Total <sup>d</sup>	26,913	100.0%	22,097	100.0%	2,303	100.0%	2,187	100.0%	148	100.0%	3,482	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

## Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	44,783	98.1%	35,641	98.1%	5,486	98.2%	3,301	98.0%	171	98.3%	4,600	97.8%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	120	0.3%	85	0.2%	21	0.4%	-	-	-	-	-	-
Adenocarcinoma <sup>e</sup>	39,036	85.5%	31,163	85.8%	4,717	84.5%	2,851	84.6%	154	88.5%	3,989	84.8%
Adenocarcinoma, NOS (8140)	31,684	69.4%	25,265	69.6%	3,920	70.2%	2,249	66.7%	132	75.9%	3,211	68.3%
Papillary adenocarcinoma, NOS (8260)	36	0.1%	27	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,115	2.4%	897	2.5%	109	2.0%	95	2.8%	-	-	125	2.7%
Mucin-producing adenocarcinoma (8481)	352	0.8%	293	0.8%	40	0.7%	19	0.6%	-	-	35	0.7%
Infiltrating duct carcinoma (8500-8503,8507,8514)	4,655	10.2%	3,723	10.2%	504	9.0%	400	11.9%	-	-	462	9.8%
Other adenocarcinoma <sup>f</sup>	1,194	2.6%	958	2.6%	139	2.5%	84	2.5%	-	-	150	3.2%
Other specific carcinomas <sup>g</sup>	3,606	7.9%	2,848	7.8%	437	7.8%	286	8.5%	-	-	366	7.8%
Islet cell carcinoma (8150-8155)	313	0.7%	259	0.7%	34	0.6%	16	0.5%	-	-	29	0.6%
Other carcinomas <sup>h</sup>	3,293	7.2%	2,589	7.1%	403	7.2%	270	8.0%	-	-	337	7.2%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,022	4.4%	1,546	4.3%	311	5.6%	151	4.5%	-	-	236	5.0%
Sarcoma and other soft tissue tumors <sup>i</sup>	33	0.1%	25	0.1%	-	-	-	-	-	-	-	-
Other specific types <sup>j</sup>	44	0.1%	35	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	784	1.7%	622	1.7%	87	1.6%	65	1.9%	-	-	91	1.9%
Total	45,645	100.0%	36,323	100.0%	5,584	100.0%	3,370	100.0%	174	100.0%	4,704	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>g</sup> Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>h</sup> Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>i</sup> Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

<sup>j</sup> Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

## Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	29,687	92.4%	21,230	93.1%	3,839	87.7%	4,120	93.2%	234	95.9%	5,450	95.2%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	296	0.9%	210	0.9%	52	1.2%	28	0.6%	-	-	31	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	286	0.9%	202	0.9%	51	1.2%	27	0.6%	-	-	27	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	26,528	82.5%	18,844	82.6%	3,384	77.3%	3,900	88.2%	211	86.5%	4,867	85.0%
Adenocarcinoma, NOS (8140)	15,228	47.4%	11,307	49.6%	1,879	42.9%	1,834	41.5%	115	47.1%	2,316	40.5%
Adenocarcinoma, intestinal type (8144)	2,730	8.5%	1,607	7.0%	431	9.8%	646	14.6%	29	11.9%	534	9.3%
Carcinoma, diffuse type (8145)	1,269	3.9%	781	3.4%	155	3.5%	305	6.9%	-	-	306	5.3%
Linitus plastica (8142)	183	0.6%	136	0.6%	19	0.4%	26	0.6%	-	-	48	0.8%
Mucinous adenocarcinoma (8470-8473,8480,8482)	436	1.4%	304	1.3%	68	1.6%	57	1.3%	-	-	67	1.2%
Mucin-producing adenocarcinoma (8481)	127	0.4%	98	0.4%	21	0.5%	-	-	-	-	26	0.5%
Signet ring adenocarcinoma (8490)	5,286	16.4%	3,749	16.4%	644	14.7%	799	18.1%	45	18.4%	1,329	23.2%
Other adenocarcinomas <sup>e</sup>	1,269	3.9%	862	3.8%	167	3.8%	225	5.1%	-	-	241	4.2%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	2,204	6.9%	1,713	7.5%	301	6.9%	113	2.6%	-	-	454	7.9%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	659	2.1%	463	2.0%	102	2.3%	79	1.8%	-	-	98	1.7%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.



Table 24.22 - continued

## Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	79	0.2%	61	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	2,205	6.9%	1,397	6.1%	507	11.6%	277	6.3%	-	-	221	3.9%
Unspecified (8000-8005)	166	0.5%	119	0.5%	21	0.5%	19	0.4%	-	-	41	0.7%
Total <sup>d</sup>	32,137	100.0%	22,807	100.0%	4,379	100.0%	4,420	100.0%	244	100.0%	5,724	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

## Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013  
Both Sexes by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	61,271	99.7%	49,492	99.7%	4,146	99.6%	6,286	99.7%	276	100.0%	9,366	99.7%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	56	0.1%	44	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma <sup>e</sup>	59,316	96.5%	47,903	96.5%	3,981	95.6%	6,122	97.1%	271	98.2%	9,088	96.7%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	54,753	89.1%	44,344	89.3%	3,458	83.1%	5,744	91.1%	247	89.5%	8,480	90.3%
Follicular carcinoma (8330-8332,8335)	2,965	4.8%	2,259	4.6%	369	8.9%	268	4.3%	-	-	420	4.5%
Oxyphilic (8290)	1,291	2.1%	1,064	2.1%	120	2.9%	78	1.2%	-	-	151	1.6%
Other specific carcinomas <sup>f</sup>	1,065	1.7%	903	1.8%	90	2.2%	58	0.9%	-	-	169	1.8%
Medullary carcinoma (8510)	1,028	1.7%	869	1.8%	89	2.1%	56	0.9%	-	-	163	1.7%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	834	1.4%	642	1.3%	72	1.7%	97	1.5%	-	-	106	1.1%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	498	0.8%	401	0.8%	34	0.8%	60	1.0%	-	-	66	0.7%
Sarcoma and other soft tissue tumors <sup>g</sup>	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types <sup>h</sup>	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	169	0.3%	122	0.2%	-	-	17	0.3%	-	-	23	0.2%
Total	61,461	100.0%	49,632	100.0%	4,163	100.0%	6,303	100.0%	276	100.0%	9,394	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>e</sup> Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>f</sup> Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

<sup>g</sup> Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

<sup>h</sup> Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.